Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 145 of 5804
-
New hope for bipolar mania? phase 3 trial of KarXT begins
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Blood test may predict who needs less immunotherapy after lung cancer surgery
Diagnosis Recruiting nowThe purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can he…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New hope for schizophrenia: KarXT enters Late-Stage trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug BNT323 faces chemo in phase 3 trial
Disease control Recruiting nowThe study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or …
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New combo aims to cure hepatitis b without lifelong pills
Disease control Recruiting nowThis is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
Prevention Recruiting nowFollowing on the heels of large implementation science projects that participated in the launch of widespread daily oral PrEP availability, investigators will launch and study the integration of novel PrEP products - beginning with the dapivirine ring- into existing PrEP programs…
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail aims to stop bile duct cancer recurrence
Disease control Recruiting nowThis study is designed as a prospective, randomized, open-label, phase II clinical trial to systematically evaluate the efficacy and safety of durvalumab combined with GEMOX/GC chemotherapy followed by lenvatinib, compared with capecitabine monotherapy, as adjuvant therapy for bi…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Stroke treatment window could expand to 72 hours in new trial
Disease control Recruiting nowThe benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for melanoma brain metastases: Two-Step treatment trial launches
Disease control Recruiting nowBrain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urg…
Phase: PHASE2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for blood cancer patients: experimental drug BGB-16673 enters phase 3 trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chron…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
Disease control Recruiting nowA Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies.
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Stroke trial aims to prevent second attacks with tailored blood thinners
Disease control Recruiting nowThe objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction. The main question it aims to answer is: among the cerebral infarction patients with …
Phase: PHASE3 • Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to boost liver cancer survival
Disease control Recruiting nowTremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%. Proton radiotherapy (RT), known for its precision and tissue-sparing advantages, has demonstra…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
Can a Two-Pronged antibody boost Chemo's power against lung cancer?
Disease control OngoingThis is a phase II clinical study to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of JS207 (anti-PD-1/VEGF bispecific antibody) combined with platinum-based doublet chemotherapy in subjects with stage II-III non-small cell lung cancer. The study co…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New daily pill could help millions lose weight and control diabetes
Disease control OngoingThe main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the s…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo aims to boost CAR-T cell staying power in lymphoma
Disease control Recruiting nowB-cell non-Hodgkin lymphoma (B-NHL) is one of the most common malignancies in China, with approximately 100,000 new cases diagnosed annually. Although immunochemotherapy, novel small-molecule targeted agents, and hematopoietic stem cell transplantation have significantly improved…
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New daily pill could help shed pounds without diabetes
Disease control OngoingThe main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for liver cancer: Triple-Drug trial launches
Disease control Recruiting nowThis is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to spare esophagus in cancer patients
Disease control Recruiting nowThis is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable …
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC